RCS - Ondine Biomedical - Steriwave deploying in eight new sites

Ondine BiomedicalAnnouncement

15/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240315:nRSO9650Ga&default-theme=true

RNS Number : 9650G  Ondine Biomedical Inc.  15 March 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Steriwave deploying in eight new sites

Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company
pioneering light-activated antimicrobial treatments to prevent and treat
healthcare-associated infections (HAIs), has made significant commercial
progress to date in 2024, ahead of management's expectations. Ondine's
Steriwave® technology is deploying in eight new healthcare facilities,
including six new hospitals. This brings the total number of hospitals to 22,
representing a 38% increase year-to-date and nearly quadruple the number a
year ago. Two orthopedic surgeon group practices in the Toronto area will also
shortly begin offering Steriwave to patients undergoing elective orthopedic
procedures.

In addition, The Ottawa Hospital (TOH) has confirmed it is significantly
expanding its use of Steriwave, building upon the success of its pilot and a
comprehensive cost-benefit assessment within spine surgeries. This expansion
means that Steriwave will now be used across an additional site, and also
extends its application from spinal surgeries to also include TOH's orthopedic
and vascular surgery patients. Annually, Steriwave will now be used prior to
approximately 2,600 surgical procedures at TOH, a threefold increase from the
Steriwave pilot.

Discussions are ongoing with medical device distributors to further expand the
commercial reach of Steriwave.

Driving this increase in hospital deployments is the growing need to reduce
avoidable hospital costs in an era of rising antibiotic resistance. Recently
published findings (https://www.canjsurg.ca/content/66/6/E550) reported a net
saving approaching C$2,600 per spine surgery patient treated with Steriwave
nasal photodisinfection and chlorhexidine skin decolonization. 1  (#_edn1)
Despite case complexity increasing over the study period, the post-surgical
infection rate dropped by 67%, resulting in estimated annual cumulative
institutional savings of $2.49 attributable to the use of the bundled protocol
with Steriwave.

The new commercial deployments of Steriwave described above beyond the TOH
expansion are paid adoptions that have begun or were agreed before the end of
February 2024:

·    The first three hospitals in Spain, including the Hospital
Universitario La Paz (HULP) in Madrid for a paid pilot of patients undergoing
elective orthopedic procedures. As anticipated by a previous announcement,
these are the first sign-ups through our distribution partner in Spain.

·    Sturgeon Community Hospital, Alberta, (Alberta Health Services (AHS),
Canada's largest integrated health system). Sturgeon Community Hospital is the
third AHS hospital to deploy Steriwave. Steriwave has been deployed for the
reduction of surgical site infections (SSIs) for patients undergoing breast
reconstruction surgeries and elective orthopedic procedures.

·    Nanaimo Regional General Hospital, British Columbia, (Island Health
Authority) has deployed Steriwave to reduce HAIs in patients undergoing hip
and knee surgeries.

·    Two orthopedic surgeon group practices in the Toronto area will also
begin offering Steriwave on a patient-pay basis to patients undergoing
elective orthopedic procedures. These groups operate from Toronto Western
Hospital, St Mary's General Hospital, and Grand River Hospital all of which
are in the Greater Toronto region in Ontario, Canada.

 

Results presented at the the prestigious SPIE Photonics West conference
(https://www.londonstockexchange.com/news-article/OBI/microbiome-research-supports-use-of-steriwave/16310998)
on 30 January 2024 in San Francisco, California showed that treatment with
Ondine's Steriwave® Nasal Photodisinfection System significantly reduces
pathogens in the nose without long-term adverse effects on the nasal
microbiome. This is an important finding to allay potential concerns as to a
possible side-effect of Steriwave treatment, which has been used in over
150,000 patients with no serious adverse events reported.

 

**ENDS**

Enquiries:

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader
innovating light-activated antimicrobial therapies (also known as
'photodisinfection'). Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection technology, in various stages of
development.

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name Steriwave®.
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns, and many other
indications.

About Steriwave®

Ondine's Steriwave® nasal photodisinfection system is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
bacteria, viruses, and fungi colonizing the nose. The photodisinfection
treatment is carried out by a trained healthcare professional and is an easy
to use, painless, two-step process. The photosensitizer is applied to each
nostril using a nasal swab, followed by illumination of the area with a
specific wavelength of red laser light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is lethal to
all types of pathogens without causing long-term adverse effects on the nasal
microbiome. A key benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81% 2  (#_edn2) -is that pathogens do not
develop resistance to the therapy.

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections, 3  (#_edn3) and the Society for
Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023,
recommend nasal decolonization for major surgical procedures. 4  (#_edn4)

 

 

 

 

 1  (#_ednref1) $2,484,856-$2,495,016 average annual net savings divided by
964 mean number of patients per year= $2,582.92 net saving per patient.
Moskven E et al. Effectiveness of prophylactic intranasal photodynamic
disinfection therapy and chlorhexidine gluconate body wipes for surgical site
infection prophylaxis in adult spine surgery. Can J Surg. 2023 Nov;66(6),
E550-E560. https://doi.org/10.1503/cjs.016922

 2  (#_ednref2) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the eradication of
MRSA. J Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

 3  (#_ednref3)
https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2

 4  (#_ednref4) Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to
prevent surgical site infections in acute-care hospitals: 2022 Update. Infect
Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAXZLLFZXLXBBX